Alpha-Synuclein-Targeting Therapies

Alpha-Synuclein Targeting Therapies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein-Targeting Therapies</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Anle138b</td>
<td>MODAG</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>AbbVie/Lundbeck</td>
</tr>
<tr>
<td class="label">NPT100-18A</td>
<td>Neuraly</td>
</tr>
<tr>
<td class="label">UCBO913</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PD01A</td>
<td>Affiris</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>AC Immune</td>
</tr>
<tr>
<td class="label">BIIB054</td>
<td>BMS</td>
</tr>
</table>

Introduction

Alpha-synuclein targeting therapies represent one of the most active areas of drug development for Parkinson's disease and related synucleinopathies. This page provides comprehensive information about [alpha-synuclein](/proteins/alpha-synuclein) biology, therapeutic approaches, clinical development pipeline, and future directions.

Overview

Alpha-Synuclein Targeting Therapies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein-Targeting Therapies</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Anle138b</td>
<td>MODAG</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>AbbVie/Lundbeck</td>
</tr>
<tr>
<td class="label">NPT100-18A</td>
<td>Neuraly</td>
</tr>
<tr>
<td class="label">UCBO913</td>
<td>UCB</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PD01A</td>
<td>Affiris</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>AC Immune</td>
</tr>
<tr>
<td class="label">BIIB054</td>
<td>BMS</td>
</tr>
</table>

Introduction

Alpha-synuclein targeting therapies represent one of the most active areas of drug development for Parkinson's disease and related synucleinopathies. This page provides comprehensive information about [alpha-synuclein](/proteins/alpha-synuclein) biology, therapeutic approaches, clinical development pipeline, and future directions.

Overview

Alpha-synuclein (alpha-syn) is a natively unfolded neuronal protein that plays a central role in the pathogenesis of Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). The aggregation of alpha-syn into toxic oligomers and fibrils is a hallmark of these neurodegenerative disorders, making it a high-priority therapeutic target["@spillantini1997"].

Therapeutic strategies targeting alpha-syn include: reducing protein production, enhancing clearance, preventing aggregation, and neutralizing toxic species. Multiple approaches are now in clinical development across various phases["@brundin2017"].

Alpha-Synuclein Biology

Structure and Function

• Protein family: Synuclein family (α-syn, β-syn, γ-syn)
• Primary expression: Presynaptic terminals in the brain
• Normal function: Synaptic vesicle trafficking, neurotransmitter release regulation
• Pathological forms: Oligomers, fibrils, Lewy bodies, glial cytoplasmic inclusions

Aggregation Mechanisms

Nucleation-dependent polymerization: The conversion from native α-syn to pathological aggregates follows a nucleation-dependent mechanism:

Key aggregation drivers:

• Gene multiplication (SNCA duplication/triplication)
• Point mutations (A30P, E46K, H50Q, G51D, A53T)
• Post-translational modifications (phosphorylation, ubiquitination)
• Metal ion binding (Fe³⁺, Cu²⁺)
• Cellular stress conditions

Key Functions in Neurodegeneration

Synaptic dysfunction: α-syn aggregation disrupts:

• Synaptic vesicle recycling
• Dopamine release
• Mitochondrial function at synapses
• Axonal transport

• Membrane pore formation by oligomers
• Mitochondrial dysfunction
• Endoplasmic reticulum stress
• Lysosomal dysfunction
• Neuroinflammation propagation

Therapeutic Approaches

1. Anti-Aggregation Strategies

Small molecule aggregation inhibitors:

• Anle138b: Oligomer modulator that binds to toxic oligomers, reducing aggregation[@wagner2013]
• Curcumin and derivatives: Natural compounds that can inhibit aggregation
• NPT100-18A: Engineered protein that prevents α-syn aggregation
• SynuClean-D: Small molecule that inhibits α-syn fibrillation

2. Immunotherapy

Active vaccination:

• PD01A (Affiris): Peptide-based vaccine targeting phosphorylated α-syn (pSer129)
• ACI-35 (AC Immune): Liposome-based vaccine targeting phosphorylated α-syn

• Prasinezumab (Roche): Monoclonal antibody targeting aggregated α-syn[@schneider2022]
• Cinpanemab (Biogen): Monoclonal antibody targeting α-syn oligomers
• BIIB054 (BMS): Monoclonal antibody targeting α-syn fibrils
• ABBV-0805 (AbbVie/Lundbeck): Monoclonal antibody targeting pathological α-syn

• Target and neutralize circulating α-syn oligomers
• Enhance microglial clearance of extracellular aggregates
• Prevent cell-to-cell transmission of α-syn

3. Gene Therapy Approaches

RNA interference (RNAi):

• SNCA-targeting shRNA: Reduces α-syn expression via viral vector delivery
• MicroRNA-based approaches: AAV-delivered miR-7 or miR-153 targeting SNCA

• ASO targeting SNCA mRNA: Reduces production of α-syn protein
• IONIS-HTTRx derivatives: Similar chemistry applied to SNCA

• GDNF delivery: Does not directly target α-syn but provides neuroprotection
• NRTN (Neurturin): Gene therapy approach for neuroprotection

4. Protein Clearance Enhancement

[Autophagy](/entities/autophagy) enhancement:

• Rapamycin/mTOR inhibitors: Enhance macroautophagy
• Trehalose: Autophagy enhancer with anti-aggregation properties
• Natural compounds: Spermidine, urolithin A

• GCase modulators: Glucocerebrosidase (GBA) modifiers
• Cathepsin D enhancers: Enhance lysosomal protein degradation
• Small molecule activators: Pharmacological chaperones

• Proteasome activators: Enhance degradation of misfolded proteins
• Heat shock protein inducers: Hsp70, Hsp90 modulators

5. Symptomatic Therapies with Disease-Modifying Potential

Neuroprotective compounds:

• Inosine: Elevates urate levels (antioxidant)
• CoQ10 and analogs: Mitochondrial function support
• Neurotrophic factors: BDNF, GDNF delivery approaches

• [NLRP3](/entities/nlrp3-inflammasome) inhibitors: Target neuroinflammation
• Minocycline: Antibiotic with anti-inflammatory properties
• Sargramostim (GM-CSF): Immunomodulation approach

Clinical Development Pipeline

Phase 3 Trials

Phase 2 Trials

Phase 1 Trials

Biomarkers for Clinical Trials

Fluid Biomarkers

• Total α-syn in CSF: Decreased in PD/DLB (seeded aggregation assay)
• pSer129 α-syn: Phosphorylated form, increased in CSF/血液
• Oligomeric α-syn: Toxic oligomer levels in CSF
• Neurofilament light chain (NfL): Neurodegeneration marker

Imaging Biomarkers

• DaTscan (FP-CIT): Dopamine transporter imaging
• PK PET ligands: Pre-synaptic terminal imaging
• α-syn PET ligands: Emerging imaging tools

Clinical Endpoints

• MDS-UPDRS: Movement Disorder Society-Unified Parkinson's Disease Rating Scale
• MoCA: Montreal Cognitive Assessment
• DATATOP endpoints: Motor symptoms, disability measures
• Non-motor symptom scales: Sleep, autonomic function

Patient Selection Criteria

Genetic Subgroups

• SNCA multiplication: Higher α-syn burden, aggressive disease
• GBA carriers: Accelerated progression, target for GCase modulators
• LRRK2 carriers: Typical α-syn pathology, different therapeutic response

Disease Stage

• Pre-motor PD: Prodromal α-syn targeting
• Early PD: Optimal window for disease modification
• Advanced PD: Symptomatic benefit, less disease modification

Biomarker Enrichment

• pSer129 positive: Confirmed α-syn pathology
• Oligomer-positive: Higher likelihood of treatment response
• [NfL](/biomarkers/neurofilament-light-chain-nfl) elevation: Active neurodegeneration

Challenges and Future Directions

Key Challenges

Emerging Approaches

• Multi-target therapies: Combined mechanisms
• Personalized medicine: Genetic stratification
• Early intervention: Pre-symptomatic treatment
• Regenerative approaches: Cell replacement, gene therapy
• Combination therapies: Multiple mechanisms simultaneously

Future Directions

• α-syn PET imaging: Better visualization of pathology burden
• Seeding assays: ultrasensitive detection of pathological α-syn
• Gene editing: CRISPR-based approaches to modify SNCA
• Stem cell therapies: Cell replacement with engineered cells

Background

The study of Alpha Synuclein Targeting Therapies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [SNCA Gene](/genes/snca)
• [Dementia with Lewy Bodies](/diseases/lewy-body-dementia)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• TREM2-Targeting Therapies
• [Antisense Oligonucleotide Therapy](/therapeutics/antisense-oligonucleotide-therapy)

External Links

• [Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org/research)
• [Parkinson's Foundation - Clinical Trials](https://www.parkinson.org/Living-with-Parkinsons/Treatments/Clinical-Trials)
• [NIH - Alpha-Synuclein Research](https://www.ncbi.nlm.nih.gov/pmc/?term=alpha-synuclein+parkinson)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
• [Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: HTT, DMPK, repeat-containing transcripts
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA

Related Analyses:

• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;